Microsomal antibodies and antibodies directed toward the receptor for thyroid-stimulating hormone (TSH) decreased in parallel while patients with Graves' disease were taking carbimazole, whereas no significant changes were observed during treatment with placebo or propranolol. The changes in autoantibody levels during carbimazole treatment were independent of changes in serum thyroxine and could have been due to a direct effect of the drug on autoantibody synthesis. Evidence for this suggestion was provided when low doses of methimazole (the active metabolite of carbimazole) were found to inhibit thyroid-autoantibody production in cultured lymphocytes. Since thyroid lymphocytes are probably a major site of thyroid-antibody synthesis in Graves' disease and methimazole is concentrated in the thyroid during treatment, a local action of the drug on antibody production seems likely. This possibility could be important in the use of carbimazole to control hyperthyroidism.
This article has been cited by other articles:
Traisk, F., Tallstedt, L., Abraham-Nordling, M., Andersson, T., Berg, G., Calissendorff, J., Hallengren, B., Hedner, P., Lantz, M., Nystrom, E., Ponjavic, V., Taube, A., Torring, O., Wallin, G., Asman, P., Lundell, G., the Thyroid Study Group of TT 96,
(2009). Thyroid-Associated Ophthalmopathy after Treatment for Graves' Hyperthyroidism with Antithyroid Drugs or Iodine-131. J. Clin. Endocrinol. Metab.
94: 3700-3707
[Abstract][Full Text]
Nyirenda, M. J., Taylor, P. N., Stoddart, M., Beckett, G. J., Toft, A. D.
(2009). Thyroid-Stimulating Hormone-Receptor Antibody and Thyroid Hormone Concentrations in Smokers vs Nonsmokers With Graves Disease Treated With Carbimazole. JAMA
301: 162-164
[Full Text]
Crescioli, C, Cosmi, L, Borgogni, E, Santarlasci, V, Gelmini, S, Sottili, M, Sarchielli, E, Mazzinghi, B, Francalanci, M, Pezzatini, A, Perigli, G, Vannelli, G B, Annunziato, F, Serio, M
(2007). Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. J Endocrinol
195: 145-155
[Abstract][Full Text]
Coco, G., Dal Pra, C., Presotto, F., Albergoni, M. P., Canova, C., Pedini, B., Zanchetta, R., Chen, S., Furmaniak, J., Rees Smith, B., Mantero, F., Betterle, C.
(2006). Estimated Risk for Developing Autoimmune Addison's Disease in Patients with Adrenal Cortex Autoantibodies. J. Clin. Endocrinol. Metab.
91: 1637-1645
[Abstract][Full Text]
Cooper, D. S.
(2005). Antithyroid Drugs. NEJM
352: 905-917
[Full Text]
Greenbaum, C. J., Harrison, L. C.
(2003). Guidelines for Intervention Trials in Subjects With Newly Diagnosed Type 1 Diabetes. Diabetes
52: 1059-1065
[Full Text]
Lucas, A., Salinas, I., Rius, F., Pizarro, E., Granada, M.L., Foz, M., SanmartI, A.
(1997). Medical Therapy of Graves' Disease: Does Thyroxine Prevent Recurrence of Hyperthyroidism?. J. Clin. Endocrinol. Metab.
82: 2410-2413
[Abstract][Full Text]
Prummel, M. F., Wiersinga, W. M., Mounts, M. Ph., Koornneef, L., Berghout, A., van der Gaag, R.
(1990). Effect of Abnormal Thyroid Function on the Severity of Graves' Ophthalmopathy. Arch Intern Med
150: 1098-1101
[Abstract]
SAKATA, S., NAKAMURA, S., MIURA, K.
(1985). Autoantibodies Against Thyroid Hormones or lodothyronine: Implications in Diagnosis, Thyroid Function, Treatment, and Pathogenesis. ANN INTERN MED
103: 579-589
[Abstract]
DUNN, J. T.
(1984). Choice of Therapy in Young Adults with Hyperthyroidism of Graves' Disease: A Brief, Case-Directed Poll of Fifty-Four Thyroidologists. ANN INTERN MED
100: 891-893
[Abstract]
Gaskin, J. H.
(1982). Exophthalmos and Treatment of Graves' Disease. JAMA
248: 2239-2239
[Abstract]
Previous
